Amylyx to Host Call on Avexitide Acquisition

CAMBRIDGE, Mass.-- Amylyx Pharmaceuticals. (NASDAQ: AMLX) (“Amylyx” or the “Company”) has announced the acquisition of avexitide from Eiger BioPharmaceuticals. This significant development was shared by the Amylyx management team, who will provide further details during a conference call and webcast scheduled for tomorrow, Wednesday, July 10, 2024, at 8:00 a.m. ET.

Participants in the United States and Canada can join the conference call by dialing +1 (800) 836-8184, while international participants can use +1 (646) 357-8785. To ensure a smooth connection, it is recommended to dial in at least ten minutes before the start time and request to join the Amylyx Pharmaceuticals call. Additionally, a live webcast of the conference will be accessible under the "Events and Presentations" section in the Investor area of Amylyx’s website. The webcast will remain available for replay for a period of 90 days following the event.

Amylyx Pharmaceuticals is a company dedicated to discovering and developing new treatment options for communities with significant unmet medical needs. The focus of the company is on addressing the challenges faced by individuals living with serious and often fatal diseases. Since its inception, Amylyx has remained steadfast in its commitment to scientific research to answer critical questions in medical science, ensuring that the needs of communities are at the forefront of its decision-making processes.

Headquartered in Cambridge, Massachusetts, Amylyx Pharmaceuticals has positioned itself at the heart of a leading hub for innovation and medical research. The company’s mission is to leverage its scientific expertise to make a meaningful impact on the lives of those affected by challenging health conditions. Amylyx's approach involves a deep engagement with the communities it serves, ensuring that their insights and needs drive the company's research and development efforts.

Amylyx’s acquisition of avexitide is a strategic move aimed at expanding its portfolio of treatment options. Avexitide, previously under the development of Eiger BioPharmaceuticals, is expected to complement Amylyx’s existing research and development initiatives. This acquisition underscores Amylyx's commitment to broadening its impact on the medical field and providing innovative solutions for patients with severe health conditions.

For individuals seeking more information about Amylyx Pharmaceuticals and its initiatives, the company encourages visits to its official website at amylyx.com. Additionally, updates and news can be followed on LinkedIn and X (formerly Twitter). Investors interested in further details about the company's financials and strategic plans are advised to visit the investor section of the Amylyx website at investors.amylyx.com.

Amylyx continues to build on its strong foundation in medical research and community engagement. The acquisition of avexitide marks another step in the company's journey to offer hope and new treatment possibilities to patients facing debilitating diseases. This latest development is expected to be a focal point of discussion during the upcoming conference call, providing stakeholders with valuable insights into the future direction of Amylyx Pharmaceuticals.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!